A client receiving talquetamab reports altered taste and difficulty swallowing. Review the trend and select the best interpretation and plan.
Trend
Choose your responses, then check the answer.
Explanation
Progressive dysgeusia, dry mouth, dysphagia, and more than 10% weight loss indicate clinically significant talquetamab oral toxicity and nutritional compromise that requires prompt evaluation and treatment review.
Quick answer Trend oral toxicity together with weight and intake.
Why this is correct Talquetamab can cause persistent oral toxicity and weight loss. Weight must be monitored regularly, clinically significant loss evaluated, and treatment withheld or discontinued according to severity.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
Oncology, transplant, and biologic safety reviewVerify the indication, immune status, infection screen, interacting medicines, current organ findings, authorized action, and measurable follow-up.